Clinical Guidelines
FDA Greenlights Repeat Use of Glaukos’ iDose® TR
-
By
February 4, 2026
-
2 min
-
1
FDA has approved re-administration of iDose TR.
-
2
iDose TR delivers travoprost intracamerally.
-
3
Approval based on clinical evidence for safety.
-
4
Enhances treatment options for glaucoma patients.
-
5
No significant corneal endothelial cell loss noted.
-
6
iDose TR shows favorable long-term safety profile.
-
7
Glaukos aims to expand patient access with repeat treatment.
-
Glaukos Corporation has received FDA approval for an NDA labeling supplement that allows the re-administration of iDose® TR, an innovative intracameral therapy for glaucoma. This decision, based on substantial clinical evidence, supports the safety and tolerability of repeated treatments. iDose TR continuously delivers travoprost inside the eye, enhancing patient access and providing ophthalmologists with flexible management options for glaucoma. The therapy has shown a favorable safety profile, ensuring no significant corneal endothelial cell loss in long-term studies.
-
1
FDA has approved re-administration of iDose TR.
-
2
iDose TR delivers travoprost intracamerally.
-
3
Approval based on clinical evidence for safety.
-
4
Enhances treatment options for glaucoma patients.
-
5
No significant corneal endothelial cell loss noted.
-
6
iDose TR shows favorable long-term safety profile.
-
7
Glaukos aims to expand patient access with repeat treatment.
Listen Tab content
